Ibogaine in New Zealand

The decision, and its reasoning

New Zealand’s position is unusually well documented, because the regulator wrote down why.

In 2007 Medsafe formed the view that ibogaine had a potential therapeutic use in treating addiction, that such treatment needed supervision, and that there was therefore a case for classifying ibogaine and its metabolite noribogaine as prescription medicines. The stated aims were to limit self-treatment and to prevent the substance being developed for recreational sale as a party pill, which was a live concern in New Zealand at the time. Medsafe put that reasoning to the Medicines Classification Committee, and the minutes of the 42nd meeting record it almost word for word. The date, 2007, comes from the Commissioner’s 2015 decision, which sets out the same account.

The Medicines Classification Committee took the question up at its 42nd meeting on 3 November 2009 and recommended prescription-medicine classification for both. Ibogaine and noribogaine were gazetted on 11 February 2010.

Prescription, not approval

Ibogaine remains an unapproved medicine in New Zealand. The two words sit oddly together and the distinction is the whole of the practical position.

Prescription-only governs who may supply it: an authorised prescriber acting within their scope of practice. Approval governs whether a regulator has assessed a specific product for safety and efficacy, and no ibogaine product has been.

A New Zealand prescriber writing for ibogaine is therefore doing so without a product monograph, an approved dose, or a manufacturer’s assurance, for a substance whose principal danger is cardiac. The regime creates a lawful route and leaves the clinical responsibility entirely with the individual clinician.

New Zealand publishes what went wrong

The most underrated feature of the New Zealand model is that when something goes wrong there is somewhere to take it, and the record of what happened becomes public.

The Health and Disability Commissioner investigated the death of a 45-year-old woman who had gone to a New Zealand clinic for opioid dependence in 2013. The investigation opened in June 2014 and the Commissioner reported on 16 June 2015. She was given six doses of ibogaine totalling 2,200 mg over roughly 24 hours, against the clinic’s own three-dose, 1,600 mg protocol. The prescribing doctor left at midday and a medically untrained assistant was the only person monitoring her. Vital-sign recording stopped. She was found dead the following morning, and the post-mortem pointed to a probable cardiac arrhythmia.

The Commissioner found the doctor in breach of four rights in the Code, covering care and skill, records, information and written consent for experimental treatment, and found the assistant and the company in breach as well.

That is what prescription regulation buys. Not safety: a woman died. What it buys is an investigation, a published finding, and a named standard that was measurably not met. In a country that has never regulated ibogaine none of those three exists, because there is no rule to have broken.

What it means in practice

Access runs through a clinician, not through a booking form. Supply outside a prescription is unlawful: section 18 of the Medicines Act 1981 makes selling or distributing a prescription medicine outside the permitted route an offence carrying up to six months’ imprisonment or a NZ$40,000 fine. Section 43 goes further than Canada does on possession and use, and makes it an offence to import, procure, receive, store, use or possess a prescription medicine without reasonable excuse, the excuse in the ordinary case being that it was lawfully supplied to you as a patient. So there is no open retreat market of the Mexican or Costa Rican kind. There have been clinics, and the case above concerned one. The regime’s answer to a clinic that fails is investigation rather than absence.

That makes New Zealand a poor destination for treatment tourism and a good model for how the practice might be regulated elsewhere. Practitioners there have been developing an explicitly local model of ibogaine treatment for over a decade, with the screening and monitoring obligations a prescription medicine attracts.

New Zealand in context

Four countries treat ibogaine as a medicine whose problem is unsupervised use, and New Zealand documented its reasoning most clearly of the four.

Its published investigation of a death has no regulatory counterpart we have found in the other three. Canada’s 2026 case is a criminal prosecution rather than a published professional-standards finding, which is a different kind of record and arrives after the fact rather than against a standard.

See the status by country table for the alternatives, and Canada for the same regime arrived at by a different route.